 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, December 1st...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $639,000.00 in Stock

This price move could be a signal that CORT may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Corcept Therapeutics (CORT, $26.25) price may drop as it broke higher Bollinger Band on Dec 04, 2023

Great West Life Assurance Co. Can lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 10.2% during the 2nd quarter, according to its most recent 13F filing...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Great West Life Assurance Co. Can

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Corcept Therapeutics (CORT Research Report), with a pric...

Corcept Therapeutics (CORT) Gets a Buy from Piper Sandler

Renaissance Technologies LLC lowered its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 1.3% during the 2nd quarter, according to the company in its most recent...

Renaissance Technologies LLC Cuts Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Truist Financial Corp trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 68.7% during the 2nd quarter, according to its most recent Form 13F filing with...

Truist Financial Corp Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) have been assigned a consensus recommendation of Moderate Buy from the seven research firms that are...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Corcept Therapeutics management to meet with Piper Sandler

This is a signal that CORT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Corcept Therapeutics (CORT, $24.91) RSI Indicator left the oversold zone on November 09, 2023

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Watchers	2,775
52-Wk Low	$17.86
52-Wk High	$34.28

Market Cap	$2.76B
Volume (M)	490,151.00
52-Wk High	$34.28
52-Wk Low	$17.86

CORT Corcept Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community